Berotralstat Consistently Demonstrates Reductions in Attack Frequency in Hereditary Angioedema (HAE) Irrespective of Baseline Attack Rate: Subgroup Analysis from the APeX2 Trial

被引：0
|
作者：
Li, H. Henry [1 ]
Best, Jessica [2 ]
Murray, Sharon [2 ]
Iocca, Heather [2 ]
Tachdijan, Raffi [3 ]
机构：
[1] Inst Asthma & Allergy, Chevy Chase, MD USA
[2] BioCryst Pharmaceut Inc, Durham, NC USA
[3] AIRE Med Los Angeles, Santa Monica, CA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2021年 / 147卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
066
引用
收藏
页码：AB22 / AB22
页数：1
相关论文
共 12 条
  • [1] Oral berotralstat treatment for 96 weeks consistently reduces hereditary angioedema (HAE) attack rates regardless of baseline attack rate
    Aygoren-Pursun, Emel
    McNeil, Donald
    Collis, Philip J.
    Desai, Bhavisha
    Tomita, Dianne K.
    Johnston, Douglas T.
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 566 - 566
  • [2] Oral Berotralstat Treatment for 96 Weeks Consistently Reduces Hereditary Angioedema (HAE) Attack Rates Regardless of Baseline Attack Rate
    Aygoren-Pursun, Emel
    McNeil, Donald
    Collis, Philip
    Desai, Bhavisha
    Tomita, Dianne
    Johnston, Douglas
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB164 - AB164
  • [3] Relative Reductions in Attack Rate With Prophylactic Berotralstat (BCX7353) in Subjects with Hereditary Angioedema (HAE): Responder Analysis from the APeX-2 Study
    Lumry, William
    Maurer, Marcus
    Zuraw, Bruce
    Banerji, Aleena
    Riedl, Marc
    Johnston, Douglas
    Aygoren-Pursun, Emel
    Jacobs, Joshua
    Gower, Richard
    Wedner, H. James
    Sitz, Karl
    Magerl, Markus
    Cornpropst, Melanie
    Elder, Jennifer
    Iocca, Heather
    Nagy, Eniko
    Murray, Sharon
    Collis, Philip
    Sheridan, William
    Christiansen, Sandra
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB105 - AB105
  • [4] Berotralstat demonstrates consistentlyllow HAE attack rates during COVID-19: subgroup analysis from the apeX-S trial
    Ford, Burnette A.
    Panovska, V. G.
    Desai, B.
    Aggarwal, K.
    Murray, S. C.
    Soteres, D. F.
    [J]. ALLERGY, 2021, 76 : 213 - 214
  • [5] Berotralstat demonstrates low hereditary angioedema (HAE) attack rates in patients switching from injectable prophylaxis
    Riedl, Marc A.
    Sheridan, William P.
    Noble, Lindsey J.
    Tomita, Dianne
    Soteres, Daniel
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 566 - 566
  • [6] SUSTAINED REDUCTION IN HEREDITARY ANGIOEDEMA ATTACK RATES FOLLOWING SWITCH TO BEROTRALSTAT: SUBGROUP ANALYSIS FROM APEX-2
    Kinaciyan, T.
    Sheridan, W.
    Desai, B.
    Tomita, D.
    Grivcheva-Panovska, V.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S29 - S29
  • [7] BEROTRALSTAT DEMONSTRATES LOW HEREDITARY ANGIOEDEMA (HAE) ATTACK RATES IN PATIENTS S WITCHING FROM INJECTABLE PROPHYLAXIS
    Riedl, M.
    Sheridan, W.
    Noble, L.
    Tomita, D.
    Soteres, D.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S26 - S27
  • [8] Durable reduction in hereditary angioedema (HAE) attack rates with berotralstat over 24 months: results from the phase 3 apeX-2 study
    Kiani, S.
    Jacobs, J. S.
    Deasi, B.
    Aggarwal, K.
    Murray, S. C.
    Iocca, H.
    Lumry, W. R.
    [J]. ALLERGY, 2021, 76 : 16 - 16
  • [9] Reduction in Attacks in Hereditary Angioedema (HAE) With Berotralstat is Consistent Regardless of Prior Prophylactic Treatment: A Subgroup Analysis of the Phase 3 APeX-2 Trial
    Anderson, John
    Gagnon, Remi
    Best, Jessica
    Murray, Sharon
    Iocca, Heather
    Sitz, Karl
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB23 - AB23
  • [10] Attack-free status across subgroups of patients with hereditary angioedema (HAE) after 96 weeks of berotralstat treatment: results from the APeX-S trial
    Reshef, A.
    Zafra, H.
    Johnston, D. T.
    Tomita, D.
    Desai, B.
    Aygoeren-Puersuen, E.
    [J]. ALLERGOLOGIE, 2023, 46 (08) : 558 - 558
12